Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 3/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7708380 | 0.86 | GABRG2 (0.38) | GABRG2GABRB3GABRA3 | |
| SCHEMBL6862438 | 0.79 | GABRG2 (0.37) | GABRG2GABRB3GABRA5GABRA3MTNR1A | |
| SCHEMBL6867159 | 0.78 | GABRG2 (0.54) | GABRG2GABRB3GABRA5 | |
| SCHEMBL6866884 | 0.78 | GABRG2 (0.53) | GABRG2GABRB3GABRA5 | |
| SCHEMBL26083962 | 0.77 | GABRG2 (0.37) | GABRG2GABRB3GABRA5MTNR1AMTNR1B | |
| SCHEMBL26084236 | 0.76 | GABRG2 (0.36) | GABRG2GABRB3GABRA5MTNR1AMTNR1B | |
| SCHEMBL6873729 | 0.75 | GABRG2 (0.47) | GABRG2GABRB3GABRA5 | |
| SCHEMBL6871583 | 0.74 | GABRG2 (0.45) | GABRG2GABRB3GABRA5 | |
| SCHEMBL26084239 | 0.74 | GABRG2 (0.38) | GABRG2GABRB3GABRA5MTNR1AMTNR1B | |
| SCHEMBL16840818 | 0.74 | GABRG2 (0.45) | GABRG2GABRB3GABRA5MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2002-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103371-A1 | Substituted imidazo [1,5-a] [1,2,4] triazolo [4,3-d] [1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | GABRG2 15/4885GABRB3 11/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.